Table 1.
Baseline demographic and disease characteristics of the Chinese subpopulation of the JACOB trial (ITT population)
| Characteristic | Total (cases) | Pertuzumab group [cases (%)] | Control group [cases (%)] |
|---|---|---|---|
| Total | 163 | 82 | 81 |
| Age | |||
| < 65 years | 61 (74.4) | 62 (76.5) | |
| ≥ 65 years | 21 (25.6) | 19 (23.5) | |
| Sex | |||
| Male | 130 | 59 (72.0) | 71 (87.7) |
| Female | 33 | 23 (28.0) | 10 (12.3) |
| Disease measurability | |||
| Measurable | 144 | 74 (90.2) | 70 (86.4) |
| Non-measurable | 19 | 8 (9.8) | 11 (13.6) |
| ECOG PS | |||
| 0 | 47 | 24 (29.3) | 23 (28.4) |
| 1 | 116 | 58 (70.7) | 58 (71.6) |
| Histological subtype (Lauren classification) | |||
| Diffuse | 16 | 9 (11.0) | 7 (8.6) |
| Intestinal | 144 | 71 (86.6) | 73 (90.1) |
| Mixed | 3 | 2 (2.4) | 1 (1.2) |
| Primary site | |||
| Gastroesophageal junction | 33 | 21 (25.6) | 12 (14.8) |
| Stomach | 130 | 61 (74.4) | 69 (85.2) |
| Number of metastatic sitesa | |||
| 1–2 | 139 | 68 (82.9) | 71 (88.8) |
| > 2 | 23 | 14 (17.1) | 9 (11.3) |
| HER status | |||
| IHC2+ and ISH+ | 31 | 14 (17.1) | 17 (21.0) |
| IHC3+ | 132 | 68 (82.9) | 64 (79.0) |
| Prior gastrectomy | |||
| Yes | 47 | 23 (28.0) | 24 (29.6) |
| No | 116 | 59 (72.0) | 57 (70.4) |
ITT intention to treat; ECOG PS Eastern Cooperative Oncology Group performance status; HER2 human epidermal growth factor receptor 2; IHC immunohistochemistry; ISH in situ hybridization
aOne patient in the control group did not have data on the number of metastatic sites available